ENGLEWOOD, Colo., March 10, 2021 /PRNewswire/ -- Ampio
Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical
company focused on the advancement of immunology-based therapies
for prevalent inflammatory conditions, today announced that it has
been invited to participate in the 33rd Annual ROTH Growth
Conference being held virtually on March
15-17, 2021.
The conference will feature presentations from public and
private companies across a variety of industry sectors, followed by
one-on-one and small group meetings, as well as expert panels and
fireside chats. Past events have featured more than 550
participating companies and drawn more than 5,000 attendees,
including institutional investors, analysts, family offices and
high-net-worth investors.
The Ampio management team will participate in one-on-one
meetings with investors and analysts during the conference.
In addition, Dr. David Bar-Or, Ampio's Founder, Director and
member of the Scientific Advisory Board, will participate as an
expert on a panel discussion on Monday,
March 15, 2021 (12:00pm EST)
titled "Therapeutics Against SARS-CoV-2 – Viral Variants Will Not
Fade Away". This meeting will represent a panel discussion of
the various developmental therapeutics for SARS-CoV-2
infection. Please note that this conference is not open to
the public and, as such, if you would like to schedule a one-on-one
meeting with Ampio / attend the conference, please contact your
ROTH representative here.
About ROTH Capital Partners
ROTH Capital Partners, LLC "ROTH" is a relationship-driven
investment bank focused on serving emerging growth companies and
their investors. As a full-service investment bank, ROTH provides
capital raising, M&A advisory, analytical research, trading,
market-making services and corporate access. Headquartered in
Newport Beach, CA, ROTH is
privately held, and employee owned. For more information on ROTH,
please visit www.roth.com.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage
biopharmaceutical company primarily focused on the development of
Ampion, our product candidate, to treat prevalent inflammatory
conditions for which there are limited treatment options. Ampio's
lead drug, Ampion, is backed by an extensive patent portfolio with
intellectual property protection extending through 2035 and will be
eligible for 12-year FDA market exclusivity upon approval as a
novel biologic under the biologics price competition and innovation
act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as
well as those associated with regulatory approvals and other FDA
decisions, the Biological License Application (BLA), the ability of
Ampio to enter into partnering arrangements,
clinical trials and decisions and changes in business
conditions and similar events, the ability to receive regulatory
approval to conduct clinical trials, that Ampion may be used to
treat ARDS induced by COVID-19, all of which are inherently subject
to various risks and uncertainties. The risks and uncertainties
involved include those detailed from time to time in Ampio's
filings with the Securities and Exchange Commission, including
without limitation, under Ampio's Annual Report on Form 10-K and
other documents filed with the Securities and Exchange Commission.
Ampio undertakes no obligation to revise or update these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor Relations
Joe Hassett
joeh@gregoryfca.com
484-686-6600
Media Contact
Katie Kennedy
katiek@gregoryfca.com
610-731-1045
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-participate-in-the-33rd-annual-virtual-roth-conference-on-march-15-17-2021-301244844.html
SOURCE Ampio Pharmaceuticals, Inc.